In this article, we will look at the 13 Best Healthcare Stocks to Buy Under $10.
How Should Investors Act Going Into H2 2025?
On June 27, Tiffany McGhee, CEO of Pivotal Advisors, appeared on CNBC to talk about the best course of action for investors amid current market dynamics. She said that going into the second half of 2025 is a great time for investors to review allocations, trim what’s hot, and reinforce underweight areas to remain aligned with long-term goals. She further stated that diversification remains the best defense against uncertainty and the best offense for what’s next in the market.
READ ALSO: 13 Cheap Healthcare Stocks with Huge Upside Potential and 10 Cheap Large Cap Stocks to Buy According to Hedge Funds.
Meghan Shue, Head of Investment Strategy at Wilmington Trust, also gave her opinion in the same interview, stating that while the market may see some choppiness into the summer, investors should stay invested, as there is a considerable opportunity in the tech sector and also some of the other more beaten-up sectors, including parts of healthcare, which has been a part of the market that nobody has really wanted to touch.
McGhee corroborated this statement, saying that she expects the healthcare sector to offer catch-up opportunities. With these trends in view, let’s look at the 13 best healthcare stocks to buy under $10.
A smiling healthcare professional, treating a patient with the PLEX platform.
Our Methodology
We used Finviz to make a list of the best healthcare stocks priced at less than $10 and chose the top 13 with the highest number of hedge fund holders as of Q1 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Note: All data was recorded on July 10.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13 Best Healthcare Stocks to Buy Under $10
13. Organon & Co. (NYSE:OGN)
Stock Price: $9.95
Number of Hedge Fund Holders: 28
Organon & Co. (NYSE:OGN) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, Organon & Co. (NYSE:OGN) announced that its VTAMA (tapinarof) cream, 1%, attained a strong recommendation in the American Academy of Dermatology’s (AAD) 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis (AD).
Organon & Co. (NYSE:OGN) stated that the recommendation highlights the cream’s status as a steroid-free and effective option for daily disease management. It does not have precautions or label warnings, no restrictions on use duration or percentage of body surface area affected, and no contraindications.
Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women’s health, established brands, and biosimilars.
12. MannKind Corporation (NASDAQ:MNKD)
Stock Price: $3.82
Number of Hedge Fund Holders: 29
MannKind Corporation (NASDAQ:MNKD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 8, Wells Fargo analyst Tiago Fauth maintained a Buy rating on MannKind Corporation (NASDAQ:MNKD) and set a price target of $9.00.
The rating was based on the company’s promising growth potential and strategic advancements, as it is making notable progress in its MNKD-101 program, according to the analyst. With a majority of the expected sites activated and patients randomized, the interim analysis is set for mid-2026. The analyst expects the MNKD-101 program to advance in the second half of 2025.
Fauth also reasoned that MannKind Corporation (NASDAQ:MNKD) has strong revenue growth, supported by a potential expansion of Afrezza into the pediatric market and Tyvaso DPI royalties. When combined with the market’s focus on tangible revenue streams, these factors justify the analyst’s optimistic rating.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases. The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.